Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK132 in Advanced Malignant Solid Tumor
NCT06166472Phase 1Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Dec 2023
- Primary completion
- Apr 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK132 in advanced malignant solid tumor, sponsored by Akeso, Inc. Primary endpoints: Dose-limiting toxicity, Adverse Event, Serious Adverse Event up to 2 years and Maximum Tolerated Dose, Recommended Phase 2 Dose up to 2 years. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
AK132
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT06166472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06166472.